Jefferies isn't saying they will miss the primary endpoint. They are saying they have a 60% chance of making the primary endpoint but the endpoint will be measured in weeks, NOT months (as some have speculated here). ODAC (FDA) according to JEFF, is likely to see the weeks measure (as opposed to month measure), as not overwhelming in the efficacy category.